A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers.

Banerji, Udai; Dean, Emma J; Pérez-Fidalgo, J Alejandro; Batist, Gerald; Bedard, Philippe L; You, Benoit; Westin, Shannon N; Kabos, Peter; Garrett, Michelle D; Tall, Mathew; Ambrose, Helen; Barrett, J Carl; Carr, T Hedley; Cheung, S Y Amy; Corcoran, Claire; Cullberg, Marie; Davies, Barry R; de Bruin, Elza C; Elvin, Paul; Foxley, Andrew; Lawrence, Peter; Lindemann, Justin P O; Maudsley, Rhiannon; Pass, Martin; Rowlands, Vicky; Rugman, Paul; Schiavon, Gaia; Yates, James; Schellens, Jan H M

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji, Udai; Dean, Emma J; Pérez-Fidalgo, J Alejandro; Batist, Gerald; Bedard, Philippe L; You, Benoit; Westin, Shannon N; Kabos, Peter; Garrett, Michelle D; Tall, Mathew; Ambrose, Helen; Barrett, J Carl; Carr, T Hedley; Cheung, S Y Amy; Corcoran, Claire; Cullberg, Marie; Davies, Barry R; de Bruin, Elza C; Elvin, Paul; Foxley, Andrew; Lawrence, Peter; Lindemann, Justin P O; Maudsley, Rhiannon; Pass, Martin; Rowlands, Vicky; Rugman, Paul; Schiavon, Gaia; Yates, James; Schellens, Jan H M.

Afiliación

Banerji U; Clinical Pharmacology and Trials, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom. udai.banerji@icr.ac.uk.
Dean EJ; Medical Oncology (Drug Development), University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.
Pérez-Fidalgo JA; Department of Oncology and Hematology, INCLIVA Biomedical Research Institute, Hospital Clínico Universitario de Valencia, CIBERONC, Valencia, Spain.
Batist G; Department of Oncology, Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada.
Bedard PL; Department of Medical Oncology, The Princess Margaret Cancer Centre, Toronto, Canada.
You B; Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Université Lyon 1, Lyon, France.
Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Kabos P; Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado.
Garrett MD; School of Biosciences, University of Kent, Canterbury, United Kingdom.
Tall M; Clinical PD Biomarker Group, The Institute of Cancer Research, Sutton, United Kingdom.
Ambrose H; IMED, AstraZeneca, Cambridge, United Kingdom.
Barrett JC; IMED, AstraZeneca, Waltham, Massachusetts.
Carr TH; IMED, AstraZeneca, Cambridge, United Kingdom.
Cheung SYA; IMED, AstraZeneca, Cambridge, United Kingdom.
Corcoran C; IMED, AstraZeneca, Cambridge, United Kingdom.
Cullberg M; IMED, AstraZeneca, Cambridge, United Kingdom.
Davies BR; IMED, AstraZeneca, Cambridge, United Kingdom.
de Bruin EC; IMED, AstraZeneca, Cambridge, United Kingdom.
Elvin P; IMED, AstraZeneca, Cambridge, United Kingdom.
Foxley A; IMED, AstraZeneca, Cambridge, United Kingdom.
Lawrence P; IMED, AstraZeneca, Cambridge, United Kingdom.
Lindemann JPO; IMED, AstraZeneca, Cambridge, United Kingdom.
Maudsley R; IMED, AstraZeneca, Cambridge, United Kingdom.
Pass M; IMED, AstraZeneca, Cambridge, United Kingdom.
Rowlands V; IMED, AstraZeneca, Cambridge, United Kingdom.
Rugman P; IMED, AstraZeneca, Cambridge, United Kingdom.
Schiavon G; IMED, AstraZeneca, Cambridge, United Kingdom.
Yates J; IMED, AstraZeneca, Cambridge, United Kingdom.
Schellens JHM; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Clin Cancer Res ; 24(9): 2050-2059, 2018 05 01.

Article en En | MEDLINE | ID: mdl-29066505

Asunto(s)

Neoplasias de la Mama/tratamiento farmacológico; Neoplasias de la Mama/genética; Fosfatidilinositol 3-Quinasa Clase I/genética; Neoplasias de los Genitales Femeninos/tratamiento farmacológico; Neoplasias de los Genitales Femeninos/genética; Inhibidores de Proteínas Quinasas/uso terapéutico; Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores; Pirimidinas/uso terapéutico; Pirroles/uso terapéutico; Adulto; Anciano; Área Bajo la Curva; Biomarcadores de Tumor; Neoplasias de la Mama/metabolismo; Neoplasias de la Mama/patología; Femenino; Neoplasias de los Genitales Femeninos/metabolismo; Neoplasias de los Genitales Femeninos/patología; Humanos; Masculino; Persona de Mediana Edad; Terapia Molecular Dirigida; Mutación; Metástasis de la Neoplasia; Estadificación de Neoplasias; Inhibidores de Proteínas Quinasas/administración & dosificación; Inhibidores de Proteínas Quinasas/efectos adversos; Inhibidores de Proteínas Quinasas/farmacocinética; Pirimidinas/administración & dosificación; Pirimidinas/efectos adversos; Pirimidinas/farmacocinética; Pirroles/administración & dosificación; Pirroles/efectos adversos; Pirroles/farmacocinética; Resultado del Tratamiento

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirimidinas / Pirroles / Neoplasias de la Mama / Inhibidores de Proteínas Quinasas / Proteínas Proto-Oncogénicas c-akt / Fosfatidilinositol 3-Quinasa Clase I / Neoplasias de los Genitales Femeninos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google